A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

WEDNESDAY, Nov. 12, 2024 (HealthDay News) -- Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new study reports. Procedures like radiation ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

He is just the fifth person in the world to be part of the clinical trial ...

Prostate cancer is the most common cancer in American men, with an estimated 333,830 new cases and 36,320 deaths projected for 2026 for the disease, according to the American Cancer ...

Having a prostate-specific antigen (PSA) test result above 4.0 ng/mL is considered abnormal and it is worth closer testing, a physician said yesterday, as he suggested individuals with a family ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

A life-extending prostate cancer drug is to be made available to thousands of men in England in a matter of weeks, after a campaign by a patient and a charity. Abiraterone has been provided on the NHS ...